openPR Logo
Press release

Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Market Size, Prevalence, Therapies and Companies by DelveInsight | Eli Lilly, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG

09-11-2024 05:58 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Chronic Lower Back Pain Treatment Market

Chronic Lower Back Pain Treatment Market

(Albany, USA) DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Lower Back Pain Market Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Chronic Lower Back Pain Market Report:
• The Chronic Lower Back Pain market size was valued approximately USD 6,227 Million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were a total of 77,300,000 prevalent cases of CLBP in 2022. It is anticipated that there would be an increase in CLBP patients in the 7MM from 2019 to 2032
• Spain had the highest prevalence of CLBP cases in the EU4 with 8,930,000 cases, followed by the UK with 6,040,000 cases in 2022
• In 2022, there were 12,700,000 cases of Chronic Lower Back Pain in Japan.
• In February 2023, Camurus withdrew the CAM2038 application once it was expanded to cover chronic pain.
• In February 2023, Rexlemestrocel-L was given the RMAT designation by the FDA for regenerative medicine advanced therapy (chronic lower back pain).
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• The Chronic Lower Back Pain epidemiology based on gender analyzed that most of the CLBP cases include female population as compared to male patient pool
• The Chronic Lower Back Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Lower Back Pain pipeline products will significantly revolutionize the Chronic Lower Back Pain market dynamics.
• In August 2024, Eli lilly announced results of a Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain (Drug: LY3016859 ISA; Drug: LY3556050 ISA; Drug: LY3526318 ISA; Drug: LY3857210 ISA)
• In July 2024, Mesoblast announced results of a Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain

Chronic Lower Back Pain Overview
Chronic lower back pain (CLBP) refers to pain that persists for 12 weeks or longer, even after an initial injury or underlying cause has been treated. It is one of the most common health problems globally and can significantly impair daily functioning and quality of life. The pain may be continuous or intermittent and can range from a dull ache to a sharp, stabbing sensation. Common causes of CLBP include herniated discs, spinal stenosis, degenerative disc disease, and muscle or ligament strain. In some cases, no specific cause is identified.

Risk factors include aging, obesity, physical inactivity, poor posture, and occupations that involve heavy lifting or prolonged sitting. CLBP can also be exacerbated by psychological factors such as stress, anxiety, and depression.

Treatment typically involves a combination of pain relief methods, including physical therapy, medications like NSAIDs, and lifestyle changes such as weight management and exercise. In severe cases, surgery may be considered. Prevention strategies focus on maintaining a healthy weight, regular physical activity, and proper posture. Managing CLBP requires a multidisciplinary approach to improve mobility, reduce discomfort, and enhance the overall quality of life.

Get a Free sample for the Chronic Lower Back Pain Market Report:
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Lower Back Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Lower Back Pain Epidemiology Segmentation:
The Chronic Lower Back Pain market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Chronic Lower Back Pain
• Prevalent Cases of Chronic Lower Back Pain by severity
• Gender-specific Prevalence of Chronic Lower Back Pain
• Diagnosed Cases of Episodic and Chronic Chronic Lower Back Pain

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Lower Back Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Lower Back Pain Therapies and Key Companies
• LY3016859: Eli Lilly and Company
• Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
• Semdexa (SP-102): Scilex Holding
• Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
• AMG0103: AnGes MG, Inc
• Duloxetine: Eli Lilly and Company
• buprenorphine: Braeburn Pharmaceuticals
• Celebrex 200mg: Pfizer
• Oxymorphone ER: Endo Pharmaceuticals
• PP353: Persica Pharmaceuticals
• Oxycodone DETERx: Collegium Pharma
• Bicifadine: DOV Pharma
• OROS hydromorphone: Mallinckrodt
• EN3324 (axomadol): Grünenthal GmbH
• ABT-712: AbbVie

Discover more about therapies set to grab major Chronic Lower Back Pain market share @ Chronic Lower Back Pain Treatment Market
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Chronic Lower Back Pain Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• Chronic Lower Back Pain Therapeutic Assessment: Chronic Lower Back Pain current marketed and Chronic Lower Back Pain emerging therapies
• Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and Chronic Lower Back Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Lower Back Pain Unmet Needs, KOL's views, Analyst's views, Chronic Lower Back Pain Market Access and Reimbursement

To know more about Chronic Lower Back Pain companies working in the treatment market, visit @ Chronic Lower Back Pain Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Chronic Lower Back Pain Market Report Introduction
2. Executive Summary for Chronic Lower Back Pain
3. SWOT analysis of Chronic Lower Back Pain
4. Chronic Lower Back Pain Patient Share (%) Overview at a Glance
5. Chronic Lower Back Pain Market Overview at a Glance
6. Chronic Lower Back Pain Disease Background and Overview
7. Chronic Lower Back Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Lower Back Pain
9. Chronic Lower Back Pain Current Treatment and Medical Practices
10. Chronic Lower Back Pain Unmet Needs
11. Chronic Lower Back Pain Emerging Therapies
12. Chronic Lower Back Pain Market Outlook
13. Country-Wise Chronic Lower Back Pain Market Analysis (2019-2032)
14. Chronic Lower Back Pain Market Access and Reimbursement of Therapies
15. Chronic Lower Back Pain Market Drivers
16. Chronic Lower Back Pain Market Barriers
17. Chronic Lower Back Pain Appendix
18. Chronic Lower Back Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-bronchitis-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Progressive Multiple Sclerosis Market: https://www.delveinsight.com/report-store/chronic-progressive-multiple-sclerosis-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-market
• Encephalitis Market: https://www.delveinsight.com/report-store/encephalitis-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Bacteremia Market: https://www.delveinsight.com/report-store/bacteremia-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Cardiac Insufficiency Market: https://www.delveinsight.com/report-store/congestive-heart-failure-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Refractory Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Egfr Non-small Cell Lung Cancer Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Market Size, Prevalence, Therapies and Companies by DelveInsight | Eli Lilly, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG here

News-ID: 3651562 • Views:

More Releases from DelveInsight Business Research

Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across 7MM, Backed by 211,550 Annual Cases and 15+ Key Therapies | DelveInsight
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM with 9% CAGR Growth, states DelveInsight
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period. In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipeline Assets, According to DelveInsight
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape. DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics and Triple-Combination Therapies | DelveInsight
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The asthma market is expected to experience sustained growth over the next decade, supported by the launch of

All 5 Releases


More Releases for Chronic

Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030 This latest report researches the industry structure,
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991 This latest report researches the
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them